Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

81. Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD?

the same effect? Search Strategy Medline OVID 1950–June week 3 2010. (exp Adrenergic β-Agonists OR exp albuterol OR salbutamol.mp OR b2 agonist.mp OR b agonist.mp OR β agonist.mp OR β 2 agonist.mp) AND (exp Administration, Inhalation OR exp ‘Nebulisers and Vaporizers’ OR (nebulised or nebuliser or nebulised or nebuliser).mp) AND (exp Dose-Response Relationship, Drug OR dose OR dosage) AND (exp Pulmonary Disease, Chronic Obstructive OR copd.mp OR coad.mp). The Cochrane Database of Systematic Reviews (...) (complete) Three Part Question In [patients admitted with acute exacerbations of COPD] is [5mg nebulised salbutamol superior to 2.5mg nebulised salbutamol] at [improving lung function and reducing length of hospital stay] Clinical Scenario While working a busy nightshift in A&E, you see a patient with an acute exacerbation of COPD. They require bronchodilators & the nurse asks you if you want 2.5mg or 5mg of nebulised salbutamol. You usually administer 5mg however wondered if 2.5mg salbutamol would have

2010 BestBETS

82. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD (Abstract)

Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD Acute exacerbations of COPD reflect in part an inappropriate host response to abnormal bacterial colonization. Orally administered inactivated nontypeable Haemophilus influenzae (NTHi) can drive a specific T-cell response that by promoting intrabronchial phagocytosis down-regulates bronchus inflammation.Subjects with recurrent exacerbations of COPD were studied (...) in a randomized, multicenter, double-blind, placebo-controlled trial, to test efficacy of an NTHi oral immunotherapeutic (HI-164OV). This report describes the outcome in 38 subjects with severe COPD defined as having an FEV(1) < or = 50% of predicted normal.Exacerbations defined as an increase in volume and purulence of sputum were reduced by 16% (not significant) in the active group. However, moderate-to-severe exacerbations (defined as requiring corticosteroid therapy) were reduced by 63% (P = .05

2010 EvidenceUpdates Controlled trial quality: predicted high

83. A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease (Abstract)

A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease To assess the effect of a helium-oxygen mixture on intubation rate and clinical outcomes during noninvasive ventilation in acute exacerbation of chronic obstructive pulmonary disease.Multicenter, prospective, randomized, controlled trial.Seven intensive care units.A total of 204 patients with known or suspected chronic obstructive pulmonary disease and acute (...) of using helium during NIV to decrease the intubation rate in acute exacerbation of chronic obstructive pulmonary disease.

2010 EvidenceUpdates Controlled trial quality: uncertain

84. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease Full Text available with Trip Pro

Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease The role of antibiotics in acute exacerbations is controversial and their efficacy when added to systemic corticosteroids is unknown.We conducted a randomized, placebo-controlled trial to determine the effects of doxycycline in addition to corticosteroids on clinical outcome, microbiological outcome, lung function, and systemic inflammation in patients hospitalized with an acute (...) exacerbation of chronic obstructive pulmonary disease.Of 223 patients, we enrolled 265 exacerbations defined on the basis of increased dyspnea and increased sputum volume with or without increased sputum purulence. Patients received 200 mg of oral doxycycline or matching placebo for 7 days in addition to systemic corticosteroids. Clinical and microbiological response, time to treatment failure, lung function, symptom scores, and serum C-reactive protein were assessed.On Day 30, clinical success was similar

2010 EvidenceUpdates Controlled trial quality: predicted high

85. (Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study Full Text available with Trip Pro

(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study Chronic obstructive pulmonary disease (COPD) is a chronic disease with a high prevalence and rapidly increasing incidence rates. The effect of self-treatment of COPD exacerbations on the severity of exacerbations during a 1-year period was examined and a cost-effectiveness analysis was performed.Patients were randomly allocated to four 2-hour self-management sessions (...) , with or without training in self-treatment of exacerbations. Patients in the self-treatment group received an action plan with the possibility to initiate a course of prednisolone (with or without antibiotics). During follow-up, all participants kept a daily symptom diary. These provided the data to calculate the frequency of exacerbations, the number of exacerbation days and mean daily severity scores.Data were analysed for 142 randomised patients (self-treatment: n = 70; control: n = 72). The frequency

2010 EvidenceUpdates Controlled trial quality: uncertain

86. Steroids for COPD Exacerbation

, Treatment Failure (Lack of resolution, worsening, or death) Harm Endpoints: Adverse Drug Effects Narrative: Chronic obstructive pulmonary disease (COPD), a term that encompasses both patients diagnosed with chronic bronchitis and emphysema, is an obstructive lung disease in many cases caused by years of tobacco smoking. It is thought that patients with COPDexacerbation’ (increased shortness of breath or change in their chronic cough and sputum) may benefit from steroids, presumably by reducing (...) Steroids for COPD Exacerbation Steroids for COPD Exacerbation – TheNNTTheNNT Systemic Steroids for Acute COPD Exacerbations 10 for prevented failed treatment In Summary, for those who took the steroids: Benefits in NNT 89.5% saw no benefit 10.5% were helped by not failing treatment 1 out of 10 were helped (preventing failed treatment) Harms in NNT 13.9% harmed by developing adverse drug effects 1 out of 7 were harmed (adverse drug effects) View As: NNT % Source: Efficacy Endpoints: Mortality

2010 theNNT

87. Antibiotics for COPD Exacerbation

Failure (Lack of resolution, worsening, or death) Harm Endpoints: Diarrhea Narrative: Chronic obstructive pulmonary disease (COPD), a term that encompasses both patients diagnosed with chronic bronchitis and emphysema, is an obstructive lung disease, in many cases caused by tobacco smoking. It is thought that patients with COPDexacerbation’ (increased shortness of breath or change in their chronic cough and sputum) may benefit from antibiotics, though the reasons for this are not well elucidated (...) Antibiotics for COPD Exacerbation Antibiotics for COPD Exacerbation – TheNNTTheNNT Antibiotics for Acute COPD Exacerbations 8 for mortality In Summary, for those who took the antibiotics: Benefits in NNT 88.4% saw no benefit 11.6% were helped by being saved from death 1 in 8 were helped (life saved) 1 in 3 were helped (preventing failed treatment) Harms in NNT 5% were harmed by developing diarrhea 1 in 20 were harmed (diarrhea) View As: NNT % Source: Efficacy Endpoints: Mortality, Treatment

2010 theNNT

88. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review

Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

89. A randomised controlled equivalence trial to determine the effectiveness and cost utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX)

A randomised controlled equivalence trial to determine the effectiveness and cost utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX) A randomised controlled equivalence trial to determine the effectiveness and cost utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX) A randomised controlled equivalence trial to determine (...) the effectiveness and cost utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX) Cross J, Elender F, Barton G, Clark A, Shepstone L, Blyth A, Bachmann A, Harvey I Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cross J, Elender F, Barton G, Clark A, Shepstone L, Blyth

2010 Health Technology Assessment (HTA) Database.

90. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis

Does tiotropium lower exacerbation and hospitalization frequency in COPD patients? Results of a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

91. Systematic review: Combination therapy with long-acting ?-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adver

-Rodriguez JA , Plaza V . Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review . Rodrigo and colleagues' systematic review of research examines an important, unresolved question relating to a common and disabling condition, chronic obstructive pulmonary disease (COPD). The trials included in the review used clinically important outcomes, unlike those evaluated a decade ago. Perhaps because, like (...) than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adverse effects Peter Anthony Frith Correspondence to Peter Anthony Frith Professor in Respiratory Medicine, Flinders University of South Australia, Bedford Park 5042, Respiratory Allergy and Sleep Services, Repatriation General Hospital, Daw Park 5041, Australia; peter.frith{at}health.sa.gov.au Statistics from Altmetric.com Commentary on: Rodrigo GJ , Castro

2010 Evidence-Based Medicine

92. Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score Full Text available with Trip Pro

Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) often require hospitalization, may necessitate mechanical ventilation, and can be fatal. We sought to develop a simple risk score to determine its severity.We analyzed 88,074 subjects admitted with an AECOPD between 2004 and 2006. We used recursive partition

2009 EvidenceUpdates

93. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients (Abstract)

A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients To investigate whether proton pump inhibitor (PPI) therapy reduces the frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease (COPD).Twelve-month, randomized, observer-blind, controlled trial.A university hospital and three city hospitals in Miyagi prefecture in Japan.One hundred patients with COPD (mean age (...) +/- SD 74.9 +/- 8.2) participated. They were all ex-smokers and had received conventional therapies for COPD, including smoking cessation and bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal ulcer were excluded.Patients were randomly assigned to conventional therapies (control group) or conventional therapies plus PPI (lansoprazole 15 mg/d; PPI group) and observed for 12 months.Frequency of common colds and COPD exacerbations.The number of exacerbations per person

2009 EvidenceUpdates Controlled trial quality: uncertain

94. Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications Full Text available with Trip Pro

Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications Article Text Therapeutics

2009 Evidence-Based Medicine

95. (Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study

(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

96. Use of dry powder inhalers in acute exacerbations of asthma and COPD Full Text available with Trip Pro

in acute exacerbations of asthma and COPD. Therapeutic Advances in Respiratory Disease 2009; 3(2): 81-91 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Adrenergic beta-Agonists /administration & Albuterol /administration & Asthma /drug therapy /physiopathology; Bronchodilator Agents /administration & Disease Progression; Ethanolamines /administration & Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive /drug therapy (...) Use of dry powder inhalers in acute exacerbations of asthma and COPD Use of dry powder inhalers in acute exacerbations of asthma and COPD Use of dry powder inhalers in acute exacerbations of asthma and COPD Selroos O, Borgstrom L, Ingelf J CRD summary This review concluded that dry powder inhalers functioned equally as well as established therapies with other inhaler devices in patients with acute asthma or chronic obstructive pulmonary disease. Given poor reporting of the review process

2009 DARE.

97. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations (Abstract)

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations Frequent chronic obstructive pulmonary disease (COPD) exacerbations are a major cause of hospital admission and mortality and are associated with increased airway inflammation. Macrolides have airway antiinflammatory actions and may reduce the incidence of COPD exacerbations.To determine whether regular therapy with macrolides reduces exacerbation frequency.We performed a randomized (...) , double-blind, placebo-controlled study of erythromycin administered at 250 mg twice daily to patients with COPD over 12 months, with primary outcome variable being the number of moderate and/or severe exacerbations (treated with systemic steroids, treated with antibiotics, or hospitalized).We randomized 109 outpatients: 69 (63%) males, 52 (48%) current smokers, mean (SD) age 67.2 (8.6) years, FEV1 1.32 (0.53) L, FEV1% predicted 50 (18)%. Thirty-eight (35%) of the patients had three or more

2008 EvidenceUpdates Controlled trial quality: predicted high

98. Review: anticholinergics but not B2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD

Review: anticholinergics but not B2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD Review: anticholinergics but not β2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: anticholinergics but not β2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD Article Text

2008 Evidence-Based Medicine

99. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. (Abstract)

Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation, and has many components including mucus hypersecretion, oxidative stress, and airway inflammation. We aimed to assess whether carbocisteine, a mucolytic agent with anti-inflammatory and antioxidation activities, could reduce the yearly exacerbation rate in patients (...) with COPD.We did a randomised, double-blind, placebo-controlled study of 709 patients from 22 centres in China. Participants were eligible if they were diagnosed as having COPD with a postbronchodilator forced expiratory volume in 1 s (FEV(1)) to forced vital capacity (FVC) ratio (FEV(1)/FVC) of less than 0.7 and an FEV(1) between 25% and 79% of the predicted value, were aged between 40 and 80 years, had a history of at least two COPD exacerbations within the previous 2 years, and had remained clinically

2008 Lancet Controlled trial quality: predicted high

100. Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation

, the Netherlands. Patients: 210 patients >40 years of age (mean age 71 y, 75% men) who were admitted to hospital for chronic obstructive pulmonary disease (COPD) exacerbation (history of increased breathlessness and >1 of the following for ⩾24 hours: increased cough frequency or severity, increased sputum volume or purulence, and increased wheeze), had a history of ⩾10 pack-years cigarette smoking, and evidence of airflow limitation (forced expiratory volume in 1 second [FEV 1 ]/forced vital capacity ratio <70 (...) Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use

2008 Evidence-Based Medicine